Background
Percutaneous renal biopsy faces three major challenges in clinical management: inherent procedural risks, inability to serially monitor disease activity, and sampling variability. These limitations underscore the demand for safer, repeatable diagnostic tools.
Objective
Our objective was to explore the potential of a liquid biopsy strategy utilizing paired blood and urine analysis via Raman spectroscopy and a 1D-CNN to facilitate the differentiation of common glomerular diseases from each other and from healthy individuals.
Methods
From January 2021 to January 2025, we collected serum and first-void morning urine from 170 biopsy-confirmed patients (81 membranous nephropathy, 36 IgA nephropathy, 33 diabetic nephropathy, 20 focal segmental glomerulosclerosis) and 21 healthy volunteers. Spectra were acquired on an Attenuated Total Reflection-8300 (ATR-8300) instrument (785 nm excitation) and preprocessed via third-order polynomial baseline correction and 13-point Savitzky–Golay smoothing. A 1D-CNN was trained on the combined spectral data; performance was assessed by accuracy, sensitivity, specificity, and Receiver Operating Characteristic - Area Under the Curve (ROC-AUC).
Results
The 1D-CNN model achieved 80.0 % accuracy, 76.2 % sensitivity, and 81.3 % specificity in five-class classification. ROC-AUCs ranged from 0.81 (FSGS) to 0.85 (IgA nephropathy), confirming robust discrimination across disease subtypes and controls. Characteristic Raman bands—e.g. phenylalanine (∼1003 cm−1), Amide I (∼1655 cm−1), and C–H stretching (2800–3000 cm−1)—differed systematically among cohorts, reflecting underlying biochemical alterations.
Conclusions
Raman spectroscopy of paired blood and urine, coupled with deep learning, provides a rapid, label-free approach for minimally invasive classification of glomerular diseases. This integrated liquid biopsy strategy may enable early detection and precise stratification in nephrology, reducing reliance on invasive biopsy and informing personalized therapy.
扫码关注我们
求助内容:
应助结果提醒方式:
